A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05970172
- Locations
- 🇧🇪
Site BE32002, Brussels, Belgium
🇹🇷Site TR90010, Ankara, Turkey
🇧🇪Site BE32001, Edegem, Belgium
A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery
- Conditions
- Interventions
- First Posted Date
- 2023-03-03
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 107
- Registration Number
- NCT05754333
- Locations
- 🇺🇸
Cleveland Clinic Florida, Weston, Florida, United States
🇺🇸AdventHealth Orlando, Orlando, Florida, United States
🇺🇸Advent Health Tampa, Tampa, Florida, United States
A Study of ASP1002 in Adults for Treatment of Solid Tumors
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 210
- Registration Number
- NCT05719558
- Locations
- 🇺🇸
University of Texas Southwestern, Dallas, Texas, United States
🇺🇸Mary Crowley Cancer Research Center, Dallas, Texas, United States
🇺🇸NEXT Oncology Virginia, Fairfax, Virginia, United States
A Study of ASP2074 in Adults With Solid Tumors
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT05646797
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸Next Oncology - Oncology, San Antonio, Texas, United States
🇯🇵National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity
- First Posted Date
- 2022-11-18
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT05621616
- Locations
- 🇧🇪
Site BE32001, Edegem, Belgium
🇹🇷Site TR90002, Ankara, Turkey
🇹🇷Site TR90001, Mersin, Turkey
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
- Conditions
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 278
- Registration Number
- NCT05536297
- Locations
- 🇺🇸
Mid Atlantic Retina - Wills Eye Institute, Philadelphia, Pennsylvania, United States
🇺🇸Rand Eye Institute, Deerfield Beach, Florida, United States
🇺🇸Ochsner Clinic Foundation, New Orleans, Louisiana, United States
Incidence and Clinical Burden of Erythropoietin Hyporesponsiveness - a Retrospective Database Analysis
- First Posted Date
- 2022-09-07
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 85259
- Registration Number
- NCT05530291
- Locations
- 🇩🇪
Site DE49001, Bad Homburg, Germany
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT05520567
- Locations
- 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
A Study About How ASP5354 Affects the Body in Healthy Adults and in Adults Whose Kidneys do Not Work Well
- Conditions
- Interventions
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT05495581
- Locations
- 🇺🇸
Advanced Pharma CR, LLC, Miami, Florida, United States
🇯🇵Sekino Clinical Pharmacology Clinic, Toshima-ku, Tokyo, Japan
🇺🇸Pinnacle Research Group, Anniston, Alabama, United States
Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study
- Conditions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 1020
- Registration Number
- NCT05381311
- Locations
- 🇺🇸
Duke Clinical Research Institute, Durham, North Carolina, United States